In order to explore the role of TP53 mutation in drug sensitivity and find out specific inhibitors for individualized treatment, we explored the GDSC database to investigate whether TP53 mutated patients have selective compounds in bladder cancer. The gene discussed is TP53; the disease is urinary bladder carcinoma.